Trial · NCT00791648

Short-term Atorvastatin's Effect on Acute Kidney Injury Following Cardiac Surgery

NCT00791648, Not applicable, Completed, Vanderbilt University Medical Center; results first posted 2017-03-06

3 sourcestrials-2026-11-12-0.5.0

Cite this record

ConductScience Library. Short-term Atorvastatin's Effect on Acute Kidney Injury Following Cardiac Surgery. Trials, record NCT00791648. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT00791648

On this page

Trial

As registered on ClinicalTrials.gov, in the graph's capture of the registry.

Title: Short-term Atorvastatin's Effect on Acute Kidney Injury Following Cardiac Surgery
NCT number: NCT00791648
Status: Completed
Phases: Not applicable
Enrollment: 653 participants, actual
Lead sponsor: Vanderbilt University Medical Center
Conditions: Acute Kidney Injury, Post-Operative Delirium, Icu Delirium, Acute Renal Failure, Delirium
Interventions: atorvastatin, placebo
First posted: 2008-11-14
Last updated: 2019-09-16
Results first posted: 2017-03-06

Source ClinicalTrials.gov

Registered outcomes16

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

List	Outcome	Time frame	Description
Primary	Number of Participants With Acute Kidney Injury	postoperative day 2
Primary	Number of Participants With Delirium	while in ICU (about 2 days)
Secondary	Number of Participants Requiring Dialysis	while in ICU (about 2 days)
Secondary	Liver Enzyme: Aspartate Aminotransferase Level	postoperative day 1
Secondary	Number of Participants With Stroke	while in ICU (about 2 days)
Secondary	Number of Participants That Died	until postoperative hospital discharge (about 7 days)
Secondary	Mitochondrial Function--mtDNA Copy Number	anesthesia induction and POD 1	mtDNA copy number
Secondary	Mitochondrial Function--lactate / Pyruvate Ratio	anesthesia induction, after CPB, and POD 1	lactate / pyruvate ratio
Secondary	Mitochondrial Function--PGC-1alpha RNA Expression	anesthesia induction and POD 1	PGC-1alpha RNA expression
Secondary	Urine Markers of Renal Injury	anesthesia induction, 30 minutes into cardiopulm bypass (CPB), after CPB, ICU admission, 6 hours postop, and Post op Day (POD) 1, 2, 3	tissue inhibitor metaloproteinase-2 x insulin-like growth factor binding protein-7

1 to 10 of 16Source ClinicalTrials.gov

See all 16 registered outcomes

Outcomes16

Each outcome the trial posted results for, in ClinicalTrials.gov's words.

Type	Outcome	Time frame	Population	Units	Measured as
PRIMARY	Number of Participants With Acute Kidney Injury	postoperative day 2		Participants	COUNT_OF_PARTICIPANTS
PRIMARY	Number of Participants With Delirium	while in ICU (about 2 days)		Participants	COUNT_OF_PARTICIPANTS
SECONDARY	Number of Participants Requiring Dialysis	while in ICU (about 2 days)		Participants	COUNT_OF_PARTICIPANTS
SECONDARY	Liver Enzyme: Aspartate Aminotransferase Level	postoperative day 1		units/liter	MEDIAN
SECONDARY	Number of Participants With Stroke	while in ICU (about 2 days)		Participants	COUNT_OF_PARTICIPANTS
SECONDARY	Number of Participants That Died	until postoperative hospital discharge (about 7 days)		Participants	COUNT_OF_PARTICIPANTS
SECONDARY	Mitochondrial Function--mtDNA Copy Number	anesthesia induction and POD 1	This marker was only measured in a subset of the total study population, chosen at random.	au	MEDIAN
SECONDARY	Mitochondrial Function--lactate / Pyruvate Ratio	anesthesia induction, after CPB, and POD 1	This marker was only measured in a subset of the total study population, chosen at random.	ratio	MEDIAN
SECONDARY	Mitochondrial Function--PGC-1alpha RNA Expression	anesthesia induction and POD 1	This marker was only measured in a subset of the total study population, chosen at random.	au	MEDIAN
SECONDARY	Urine Markers of Renal Injury	anesthesia induction, 30 minutes into cardiopulm bypass (CPB), after CPB, ICU admission, 6 hours postop, and Post op Day (POD) 1, 2, 3	This marker was only measured in a subset of the total study population, chosen at random.	(ng/ml)^2/1000	MEDIAN

1 to 10 of 16Source ClinicalTrials.gov

See all 16 outcomes

Results by group118

Each measurement the trial posted, group by group, in the words and numbers it posted.

Outcome	Group	Value	Spread	Units
Number of Participants With Acute Kidney Injury	Statin	64		Participants
Number of Participants With Acute Kidney Injury	Placebo	60		Participants
Number of Participants With Delirium	Statin	69		Participants
Number of Participants With Delirium	Placebo	75		Participants
Number of Participants Requiring Dialysis	Statin	5		Participants
Number of Participants Requiring Dialysis	Placebo	3		Participants
Liver Enzyme: Aspartate Aminotransferase Level	Statin	49	95% Confidence Interval 25 to 105	units/liter
Liver Enzyme: Aspartate Aminotransferase Level	Placebo	52	95% Confidence Interval 27 to 146	units/liter
Number of Participants With Stroke	Statin	10		Participants
Number of Participants With Stroke	Placebo	7		Participants

1 to 10 of 118Source ClinicalTrials.gov

See all 118 results by group

Participant flow6

How many started, completed or left each group, period by period.

Period	Milestone	Group	Participants
Overall Study	STARTED	Statin	308
Overall Study	STARTED	Placebo	309
Overall Study	COMPLETED	Statin	308
Overall Study	COMPLETED	Placebo	307
Overall Study	NOT COMPLETED	Statin	0
Overall Study	NOT COMPLETED	Placebo	2

Source ClinicalTrials.gov

Adverse events50

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

Type	Event	Organ system	Group	Affected	At risk	Events
other	Fever	Infections and infestations	Statin	50	308	125
other	Fever	Infections and infestations	Placebo	52	307	117
other	Tachycardia	Cardiac disorders	Statin	49	308	215
other	Tachycardia	Cardiac disorders	Placebo	42	307	190
other	Hypotension	Cardiac disorders	Statin	188	308	1,032
other	Hypotension	Cardiac disorders	Placebo	192	307	1,073
other	Vasoplegia	Cardiac disorders	Statin	120	308	342
other	Vasoplegia	Cardiac disorders	Placebo	118	307	357
other	Decreased Cardiac Output	Cardiac disorders	Statin	187	308	643
other	Decreased Cardiac Output	Cardiac disorders	Placebo	194	307	623

1 to 10 of 50Source ClinicalTrials.gov

See all 50 adverse events

Adverse event totals6

The totals the trial posted for each group.

Total	Group	Affected	At risk
Total, all-cause mortality	Statin
Total, all-cause mortality	Placebo
Total, other adverse events	Statin	308	308
Total, other adverse events	Placebo	307	307
Total, serious adverse events	Statin	14	308
Total, serious adverse events	Placebo	19	307

Source ClinicalTrials.gov

Papers3

The papers the trial lists on ClinicalTrials.gov.

PMID	Listed as	Source
21334433	DERIVED	PubMed
26906014	DERIVED	PubMed
29223955	DERIVED	PubMed

Grants0

The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.

None in this release.

Trial comparisons6

Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.

Comparison	Source
Statin vs Placebo: Number of Participants With Acute Kidney Injury	Trial comparisons
Statin vs Placebo: Number of Participants That Died	Trial comparisons
Statin vs Placebo: Number of Participants With Delirium	Trial comparisons
Statin vs Placebo: Number of Participants With Stroke	Trial comparisons
Statin vs Placebo: Number of Participants Requiring Dialysis	Trial comparisons
Statin vs Placebo: serious adverse events	Trial comparisons

Tests0

The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.

None in this release.

Data dates

The day each source was copied for this release.

ClinicalTrials.gov: 2026-11-12; ClinicalTrials.gov
Results, from AACT: 2026-03-23; AACT
NIH grant links: 2026-11-13; NIH RePORTER

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this trial from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/trials/v1/NCT00791648

GET https://conductscience.org/api/trials/v1/NCT00791648/results?page=2

API reference For AI assistants